

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

TAKEDA PHARMACEUTICAL COMPANY )  
LIMITED, TAKEDA PHARMACEUTICALS )  
INTERNATIONAL GMBH, TAKEDA )  
PHARMACEUTICALS USA, INC., TAKEDA )  
PHARMACEUTICALS AMERICA, INC., and )  
OREXIGEN THERAPEUTICS, INC., )

Plaintiffs, )

v. )

C.A. No. 15-451 (RGA)

ACTAVIS LABORATORIES FL, INC., )

Defendant. )

~~IN PROPOSED~~ **CLAIM CONSTRUCTION ORDER**

As set forth in its Memorandum Opinion of June 6, 2016 (D.I. 60), the Court has determined that the following terms of U.S. Patent Nos. 7,462,626 (the "'626 patent") and 8,916,195 (the "'195 patent") shall have the following meanings:

1. "administering" ('626 and '195 patents): "delivering into the body;"
2. "a weight loss effective amount of a first and second compound" ('626 patent): "a weight loss effective amount of a first and second compound, in combination;"
3. "having reduced adverse effects" (claim 11 of the '195 patent): this phrase from the preamble of claim 11 is not limiting.

SO ORDERED this 10 day of June, 2016.



UNITED STATES DISTRICT JUDGE